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Open access under CC BY-NC-ND license.Protein kinase Ca (PKCa) is a member of the AGC (which
includes PKD, PKG and PKC) family of serine/threonine
protein kinases that is widely expressed in mammalian
tissues. It is closely related in structure, function and
regulation to other members of the protein kinase C
family, but has specific functions within the tissues in
which it is expressed. There is substantial recent evi-
dence, from gene knockout studies in particular, that
PKCa activity regulates cardiac contractility, atherogen-
esis, cancer and arterial thrombosis. Selective targeting
of PKCa therefore has potential therapeutic value in a
wide variety of disease states, although will be techni-
cally complicated by the ubiquitous expression and
multiple functions of the molecule.
Introduction
Protein kinase C (PKC) is a family of serine/threonine
protein kinases that regulate various cellular functions,
including adhesion, secretion, proliferation, differentiation
and apoptosis. The family is classified into three groups on
the basis of the arrangement of their regulatory domains
w2[1]. Conventional isoforms (cPKC; a, b, g) contain a
diacylglycerol (DAG)/phorbol ester-binding C1 domain
and a Ca2+-binding C2 domain. Novel isoforms (nPKC; d,
e, h, u) also contain C1 domains, but their C2 domains are
unable to bind Ca2+. Atypical isoforms (aPKC; z and i/l)
lack a C2 domain and have an atypical C1 domain, and are
therefore regulated independently of Ca2+ or DAG.
Here we focus on PKCa because of recent evidence,
particularly derived from genetic studies, implicating this
kinase in several major disease processes [2–4], and
because of the multiple approaches that may be adopted
to target PKCa pharmacologically [5–7]. PKCa is widely
expressed and being a conventional PKC isoform, it may
be regulated downstream of the multitude of receptors
that couple to activation of phospholipase C, includingGq-
coupled GPCRs (G-protein-coupled receptors), growth fac-
tor receptors and adhesion receptors. Pharmacological
studies have shown PKCa to regulate multiple biological
processes, including cell proliferation, apoptosis, differen-
tiation,migration and adhesion. These roles are described
and discussed elsewhere [1,8–10] and are outside of the
scope of this article. Themore recent introduction of PKCa
gene knockout (Prkca/) mice has provided definitive
evidence for the function of this kinase in physiological
processes including insulin coupling to PI3kinase [11],
and immune cell functions such as IgG class switchingCorresponding author: Poole, A.W. (a.poole@bris.ac.uk).
8 0165-6147  2009 Elsevier Ltd. All rights reserv[12] and down-regulation of theT cell receptor [13], such as
prostate and breast cancer, heart failure and pulmonary
disease.
PKCa gene knockout mice are now also revealing
critical roles for this gene in disease processes. In this
opinion, we concentrate on the role of PKCa in the three
best studied of these: cardiovascular dysfunction, arterial
thrombosis and cancer (Fig. 1). We suggest that, through a
variety of pharmacological strategies (Box 1), PKCa may
emerge as a key target in the future treatment and man-
agement of these diseases.
PKCa in cardiovascular disease regulation
Heart failure
It has been established that various PKC isoforms, in-
cluding PKCa, contribute to impaired left ventricular
filling and ejection in heart failure [6]. PKCa is both
necessary and sufficient to induce cardiomyocyte hyper-
trophy - an adaptive mechanism triggered by decreased
cardiac output and, if sustained, leading to heart failure
and death - by an increase in protein synthesis, protein-
DNA ratio, and cell surface area [14]. Further, PKCa
antisense treatment reduces phenylephrine-induced
increases in a-actin mRNA and atrial natriuretic peptide
secretion [15], thereby causing a loss of some markers of
pathological hypertrophy. Overexpression of PKCa also
increases cardiomyocyte surface area and atrial natriure-
tic peptide expression, indicating that PKCa activation
induces cardiomyocyte hypertrophy [16].
This regulation of cardiac hypertrophy translates into
end-stage heart failure, and in animal models of this
disease, expression and activity of PKCa are up-regulated
[17]. Ablation ofmyocardial PKCa by targeted gene knock-
out leads to increased myocardial contractility, whereas
transgenic overexpression of PKCa results in ventricular
dysfunction and alterations in Ca2+ homeostasis [3]. The
mechanism of PKCa-dependent depression of myofila-
ment contractility involves phosphorylation of the cardiac
troponins cTnI and/or cTnT functionally important in
controlling maximum tension, ATPase activity, and
Ca2+ sensitivity of the myofilaments [18].
Atherosclerosis
Atherosclerosis is a disease of large and medium-sized
vessels that involvesmultiple cells and processes including
endothelial dysfunction, inflammation and proliferation.
In the arterial wall the disease is characterized by the
emergence in the intima of atherosclerotic fatty streaks,
later transforming into plaques, consisting of connectiveed. doi:10.1016/j.tips.2009.10.006 Available online 5 December 2009
Figure 1. PKCa plays key physiological and pathological roles. The ubiquitously expressed protein kinase PKCa plays roles in multiple cellular processes, including many
not detailed in the Figure. Depicted are the three areas discussed principally in the text where PKCa has been shown to play a role in regulating cardiac and vascular
function, platelet function and thrombosis, and cellular proliferation and migration in cancers. In brief, PKCa negatively regulates myocardial contractility, positively
regulates angiogenesis and monocyte adhesion to endothelial cells in atherosclerosis development, positively regulates platelet aggregation and thrombus formation in
arteries and variously regulates tumor progression, depending upon cell type and nature of the cancer.
Opinion Trends in Pharmacological Sciences Vol.31 No.1tissue and some smooth muscle cells (SMCs). It is accom-
panied by thickening and hardening (sclerosis) of the
arterial wall, loss of elasticity due to infiltration of the
intima with mononuclear cells, SMCs, and increased endo-
thelial cell depositions. Atherosclerosis designates a
special form of arteriosclerosis that is additionally charac-
terized by the occurrence of foam cells, that is, lipid-laden
macrophages and SMCs that may rupture and release
their contents into the lesional areas. There is substantial
evidence that PKCa plays key roles in these processes.
Endothelial cell proliferation
Pathological angiogenesis has been implicated in a number
of vascular diseases, including unstable atherosclerotic
plaque development [19]. Although there are some reports
to the contrary [20,21], PKCa has generally been shown to
be a positive regulator of angiogenesis [22], involving the
processes of endothelial cell migration, adhesion and tube
formation mediated by vascular endothelial growth factor
(VEGF).
In vivo, knockdown of PKCa prevents myocardial vessel
formation in a murine model of myocardial infarction [23].
There seems to be positive feedback between the two
signalling components, PKCa and VEGF, because VEGF
expression in endothelial cells depends on PKCa, but in
turn VEGF leads to activation of PKCa [24]. Overexpres-
sion of a PKCa pseudosubstrate inhibitory peptide also
slows the rate of endothelial cell migration [25]. Addition-
ally, PKCa mediates interleukin-1b-induced expression
of matrix metalloproteinase-2, a molecule implicated in
angiogenesis [26].Endothelial barrier function
Endothelial permeability is tightly regulated by a balance of
contractile forces generated by the cytoskeleton and
adhesive forces generated by cell–cell and cell–matrix con-
tact [27]. Early studies suggested that PKC mediates the
acute rise in endothelial permeability in vitro, via receptor-
mediated (e.g. through thrombin, histamine or bradykinin
receptors), or receptor-independent (by oxidants or shear
stress) increases in phospholipase C activity [28]. Sub-
sequently, several studies have narrowed this effect specifi-
cally to PKCa and its role in endothelial cell contraction and
disassembly of VE-cadherin junctions [29,30].
At the molecular level, the mechanism might involve
PKCa-dependent regulation of transient receptor potential
canonical-1 (TRPC-1) channels [31] and Rho GTPases
[32,33]. The increase in pulmonary endothelial cell per-
meability caused by TNFa is also associated with an
increase in PKCa activity [34], and protein phosphatase
type 2B (PP2B), which might regulate PKCa activity, is
also implicated in regulating the permeability of pulmon-
ary endothelial cells [35].
Lastly, endothelial permeability is altered in diabetes
mellitus, and PKCa has been shown to mediate glucose-
induced increases in endothelial cell permeability [36].
Therefore, there is high consensus among data supporting
the idea that PKCa positively regulates endothelial per-
meability through various molecular mechanisms.
Oxidative stress and monocyte adhesion
Endothelial cell dysfunction elicited by oxidative stress
plays a critical role in the pathogenesis of atherosclerosis9
Box 1. Approaches to targeting PKCa
Several approaches are used to target PKCa therapeutically, as
summarized in Figure I.
1. ATP (adenosine triphosphate) binding site
The ATP binding site is attractive for drug targeting, although
selectivity may be difficult to achieve due to conservation of sequence
and structure for this domain within the PKC family. The high
concentration of ATP competes also with inhibitors at this site,
decreasing their apparent activity. However, this site is still highly
attractive for drug development, particularly by structure-based
approaches, which are proving useful for PKCu inhibitors [71]. A
publicly available crystal structure for PKCa is still absent, and is
clearly a requirement for future development.
Some bisinolylmaleimides, derivatives of staurosporine, show
good selectivity within the PKC family. Ruboxistaurin (LY333531)
and enzostaurin (LY317615) are designed to selectively target PKCb,
although a recent report suggests that ruboxistaurin may inhibit PKCa
equipotently [72]. Both enzastaurin and ruboxistaurin are well
tolerated [73,74]. Enzastaurin shows promise in phase I trials for the
treatment of advanced cancer [75]. Ruboxistaurin has completed
phase III trials for the management of diabetic retinopathy [70,74],
principally through targeting PKCb.
2. Peptide substrate mimetics
Peptide substrate mimetics are short peptides that resemble the
preferred substrate sequence for PKCa, often mimicking the pseudo-
substrate domain, and compete for substrate binding. In addition, a
small-molecule inhibitor, chelerythrine, competitively binds to the
substrate-binding pocket, although its specificity for PKCa is poor [76].
3. C1 domain
The C1 domain binds diacylglycerol (DAG) and phorbol esters.
Bryostatin is a macrocyclic lactone that competes with DAG for
binding [77], and simplified analogues have been designed with
improved activity [78]. Calphostin C also binds PKCa, and other PKC
isoforms, at the C1 domain. The inhibition is irreversible, and requires
prior light activation of the molecule [79].
4. C2 domain
The C2 domain binds Ca2+ and mediates interaction with proteins
[80], in particular Receptors-for-Activated-C-Kinase (RACKs) [81].
RACK peptides therefore disrupt the localization of PKCs to their
substrates, thereby effectively inhibiting their activity. This inhibition
has been shown most extensively for PKCd, where KAI-9803 is
undergoing clinical trial for cardiac ST segment elevation of
cardiogram in patients with myocardial infarction [82]. PKCa
interacts with fascin and lamin A, and inhibition of these interactions
might disrupt cytoskeleton- and nucleus-dependent signalling
[83,84].
5. Gene therapy
Although not shown in Figure I, an antisense drug, aprinocarsen
(ISIS 3521, LY900003), has been used to reduce expression of PKCa.
This drug has undergone phase III clinical trials for the treatment of
various human tumors [61] but has not progressed through to the
clinic, due to non-achievement of efficacy endpoints and associated
toxicity.
Figure I. PKCa domain structure mapped against pharmacological inhibitors. The structure comprises an N-terminal regulatory domain, consisting of the diacylglycerol
(DAG)-binding C1 domain and the Ca2+-binding C2 domain, and a C-terminal catalytic domain, consisting of an ATP-binding pocket followed by the substrate-binding
domain. Each component of the molecule is a potential target for pharmacological intervention, as indicated by the drugs listed below the domains. Thus, bryostatin
and calphostin C target the C1 domain, RACK peptides mimic the C2 domain region of protein-protein interaction, staurosporine and its derivatives target the ATP
binding pocket, whilst peptides that mimic the pseudosubstrate domain, and chelerythrine, bind to the substrate-binding domain. Not illustrated here is the use of
genetic tools, such as antisense drugs (e.g. aprinocarsen), that can alter the expression of the protein in cells and tissues.
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when excessive free radicals react with the lipoproteins.
In turn, these oxidized LDLs (Ox-LDLs) become deposited
in the arterial walls and can lead to plaque development by
stimulating macrophage uptake and foam cell formation.
A detrimental feedback loop operates in endothelial
cells, where superoxides lead to generation of Ox-LDLs,
which in turn stimulate further superoxide generation.
Fleming et al. [38] have shown that Ox-LDL stimulation
of endothelial cells leads to uncoupling of endothelial nitric10oxide synthase (eNOS) from its generation of nitric oxide,
and a greater accumulation of superoxide free radicals. The
signalling pathway in endothelial cells from Ox-LDL to
eNOS has been attributed to inactivation and down-regu-
lation of PKCa, which results in diminished phosphoryl-
ation of eNOS on Thr-495 [38].
Additionally, PKCa in inflammatory cellsmightmediate
their adhesion to and interaction with endothelial cells.
The adhesion of circulating monocytes to endothelial cells
contributes importantly to the inflammatory aspects of
Opinion Trends in Pharmacological Sciences Vol.31 No.1atherogenesis, which describes the development of athero-
sclerotic plaques.Pre-incubationofmonocyteswithGo¨6976,
the inhibitor of classical PKC isoforms, significantly reduces
monocyte adhesion to HUVECs (human umbilical vein
endothelial cells) [39]. Another inflammatory mediator,
apolipoprotein CIII, a constituent of apolipoprotein B,
enhances the adhesion of monocytes to endothelial cells
via PKCa-mediated b1-integrin activation [40]. Lastly,
endothelial cell PKCa is important in also regulating
inflammatory cell adhesion, through expression of the
adhesion molecule PECAM-1 [41], and through regulating
exocytosis and surface expression of P-selectin, which med-
iates neutrophil-endothelial cell interaction [42].
In summary, although there is a mixed picture in terms
of the role of PKCa in atherogenesis and cardiomyocyte
hypertrophy, there is reasonable consensus that, on bal-
ance, inhibitors of PKCa are likely to be useful in the
management of these diseases.
Platelet function and thrombosis
Platelets play a central role inmediating atherothrombosis,
characterized by an unpredictable atherosclerotic plaque
disruption, and are therefore the target of numerous thera-
pies aimed at reducing their activity, particularly in the
prevention of coronary artery thrombosis in heart attacks
[43]. PKC has been established, largely by pharmacological
studies, as a major regulator of multiple platelet activities
[44], and it is increasingly clear that thedifferent isozymesof
PKC expressed in platelets perform distinct functions.
On activation, platelets release a multitude of active
substances from secretory granules, essential for platelet
pro-aggregatory responses and development of a stable
thrombus in arteries. Yoshioka et al. [45] have analyzed
the mechanisms governing Ca2+-induced secretion of a-
granules and dense-core granules in permeabilized human
platelets, and identified PKCa as an essential component
of the mechanism. Using similar biochemical approaches,
the same group demonstrated that PKCa is also involved
in the regulation of Ca2+-induced platelet aggregation [46].
Pula et al. [47] have shown that two tyrosine kinases, Syk
and Src, physically interact with PKCa, leading to distinct
functional consequences. Although they found that PKCa
activity was dependent on Syk, Syk activity was not
regulated by PKCa; however, Src activity was negatively
regulated by PKCa. These results suggest that PKCa is an
important factor in the complex interaction with tyrosine
kinases for regulation of functional activities in platelets.
Additionally, in a recent elegant study reconstructing the
signalling pathway regulating platelet integrin aIIbb3 in a
heterologous cell system, it was shown that PKCa expres-
sion is required for activation of the integrin through the
Rap1 pathway [48]. Key molecular functions of platelet
activation are therefore mediated by PKCa.
On the basis of pharmacological data, the specificity of
the role played by PKCa has been a contentious issue, due
to the lack of selectivity of the reagents available. We have
therefore developed a genetic approach using PKCa knock-
out (Prkca/) mice to determine the role of PKCa in
regulating platelet function and thrombus formation [4].
With regard to the suggested role of PKCa in regulating
secretion of dense- and a-granules [45], we were able toconfirm definitively that secretion of these granules was
substantially diminished in Prkca/ platelets. Prkca/
platelets showed significantly reduced functionally
relevant phosphorylation on Ser95 of synaptosomal associ-
ated protein SNAP-23, an essential component of the
membrane fusion machinery and an important regulator
of vesicle docking and fusion [4]. This observation therefore
may potentially explain the observed secretion defect in
PKCa-deficient platelets.
In addition, Prkca/ platelets show a marked knock-
down in activation of integrin aIIbb3 in response either to
thrombin or collagen-related peptide, paralleling a deficit in
their ability to undergo aggregation at submaximal concen-
trations of agonist. This is also consistent with the impaired
ability of Prkca/ platelets to form a thrombus in vitro in
bloodflowing overa collagen-coated surface and inan in vivo
laser-induced model of thrombus formation (Fig. 2). The
defect in secretion was shown, however, to be the central
significant event, because addition of exogenous ADP (ade-
nosine diphosphate), the major constituent released from
platelet dense granules, rescued the deficits in responses
seen in Prkca/ platelets, confirming that granule
secretion is likely to be the primary function for PKCa.
These findings, together with the fact that Prkca/
mice do not demonstrate any evidence of overt bleeding,
have revealed that PKCa is a potential drug target for
antithrombotic therapy, because selective inhibitors would
be expected to exert a major effect on thrombus formation
while sparing primary platelet adhesive functions.
PKCa in cancer
PKCa has long been recognized to have a role in regulating
aspects of tumor growth and development [10], although
this role is clearly complex and highly tissue-dependent
because in some cases it acts as a tumor promoter, and in
others it functions as a tumor suppressor. Nonetheless,
PKC in general has, for many years, been a drug target for
the treatment of cancer. Pharmacological approaches to
control of cancer by PKC inhibitors have been discussed
elsewhere [7,49] and some of these approaches for PKCa
are discussed in Box 1.
Its most consistent role is probably regulation of cell
motility, and certainly PKCa activation can result in
increased cell motility in several in vivo and in vitro cancer
models, the effect of which may be reversed on PKCa
inhibition[50,51].However, the predominant overall picture
is of a lack of consistency, which can be illustrated by its
differing expression patterns in different tumors. Overex-
pression of PKCa has been demonstrated in tissue samples
of prostate, endometrial, high-grade urinary bladder and
hepatocellular cancers[52–55], while for haematological
malignancies up- or down-regulation of PKCa has been
described [56], and inbasal cell carcinomaandcoloncancers,
down-regulation of PKCa has been observed [2,57]. Amixed
picturealso pertains tobreast cancer cells,where it has been
studied extensively. Whereas activation or over-expression
of PKCa has been shown in breast cancer cells and in breast
tumor samples by some [58,59], down-regulation has been
demonstrated by others [60].
In terms of cancer therapeutics, PKCa has been a target
for the drug aprinocarsen (ISIS 3521; see also Box 1), a11
Figure 2. PKCa plays a critical role regulating platelet function and thrombosis in arteries. Platelets are the smallest cellular component of the blood, and flow close to the
endothelial lining of arteries continually surveying the vessel for breaches in endothelial integrity. In the main panel platelets are depicted encountering such a breach,
exposing subendothelial collagen to which platelets adhere and activate. Critical for the rapid build up of a platelet aggregate, or thrombus, is the release of positive
feedback mediators, many of which, including ADP which acts on its receptors P2Y1 and P2Y12, are contained in secretory granules in platelets. The expanded inset figure
illustrates that PKCa plays a crucial role mediating signals from the platelet collagen receptor, GPVI, to release of granule contents, including ADP, and also to activation of
the major adhesion molecule, integrin aIIbb3. This integrin bridges platelets through binding the plasma protein fibrinogen. Platelet–platelet interaction and subsequent
build up of a thrombus in arteries is therefore dependent upon platelet PKCa. Arterial thrombus formation is the major occlusive event underlying vessel blockage in heart
disease and thrombotic stroke, and therefore platelet PKCa may represent a novel target for therapeutic intervention.
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targets the 3’-untranslated region of human PKCamRNA,
leading to decreased expression of the protein [61]. Apri-
nocarsen has been studied as a single agent, as well as in
combination with standard chemotherapeutics, in cancer
patients in over 20 trials from phase I to phase III
(reviewed in [61,62]). The studies include individuals with
non-small cell lung cancer [63], colon [64], ovarian [65],
breast [66] and prostate cancers [67] and non-Hodgkin’s
lymphoma [68]. Although encouraging results have been
observed in phase II trials, disappointingly aprinocarsen
has failed to meet efficacy endpoints in phase III trials
when used in combination with conventional chemother-12apy for late-stage lung cancer [69,70]. Reasons for this lack
of efficacy could be manifold, including lack of prior screen-
ing of patients for expression levels of PKCa, dose
reduction due to toxicity during the trial and driving of
cell proliferation by other related PKC isoforms [69].
Conclusions
PKCa plays important roles in several cellular processes
and pathologies, involving cancer, cardiovascular dis-
orders, atherogenesis and thrombosis. Its ubiquity and
multiple roles, however, present a potential difficulty in
its use as a drug target, although the mutual functional
redundancy of various PKC isoforms might help to
Opinion Trends in Pharmacological Sciences Vol.31 No.1overcome possible unwanted effects of specific pharmaco-
logical intervention. It is clear, for instance, that thrombus
formation is markedly diminished in the Prkca/ mouse,
whereas haemostasis is normal [4]. This functional redun-
dancy with related PKC isoforms may also obscure other
potential roles for PKCa, determined in particular from
gene knockout strategies. There are clearly many strat-
egies that can be adopted to target this kinase therapeuti-
cally (Box 1), and in this regard a key advance will be the
determination of the crystal structure of the catalytic
domain of PKCa. It will be important to continue devel-
oping strategies for PKCa targeting in the future, because
specific drug targeting could have great value in the treat-
ment of multiple disease states.
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